Based on previous reports, we propose a practical guide to choose dabigatran 150 mg twice daily or apixaban 5 mg twice daily for patients with atrial fibrillation. We recommend the use of dabigatran 150 mg twice daily for patients with atrial fibrillation who have a high risk of embolism (e.g., ischemic stroke on other oral anticoagulants, presence of left atrial appendage thrombus) and a low risk of bleeding. However, the prevalence of such patients with atrial fibrillation is considered low because patients with atrial fibrillation with a high risk of embolism usually have a high risk of bleeding. In most other patients with atrial fibrillation, the use of apixaban 5 mg twice daily should be considered.
Introduction
Dabigatran, apixaban, rivaroxaban, and edoxaban are direct oral anticoagulants (DOACs) that have been shown to prevent embolisms in patients with atrial fibrillation (AF) in large clinical trials, with each investigating over 10,000 patients. Among the 4 DOACs, dabigatran 150 mg twice daily is the sole drug shown to be superior to warfarin for preventing ischemic stroke in patients with AF 1) . In addition, only dabigatran 150 mg twice daily and apixaban 5 mg twice daily have been shown to be superior to warfarin for preventing "stroke or systemic embolic events" in patients with AF 1, 2) . On the other hand, the risk of gastrointestinal bleeding with dabigatran 150 mg twice daily is higher than that with warfarin 1) . The benefit in terms of ischemic stroke prevention with dabigatran 150 mg twice daily is in exchange for a higher risk of gastrointestinal bleeding.
Based on these results, previous reports on choices of DOACs for patients with AF described that the use of dabigatran 150 mg twice daily should be considered in patients with AF with high embolic and low bleeding risk [3] [4] [5] [6] . For other patients with AF, apixaban can be most widely used for its safety profile 3, 4) . However, there is no practical guide to choose dabigatran 150 mg twice daily or apixaban 5 mg twice daily for patients with AF. Herein, we propose a practical guide focused on choices of these agents for patients with AF.
Indications of DOACs for Patients with AF
In patients with non-valvular AF, evaluation using the CHADS 2 (Congestive heart failure, Hypertension, Age ≥ 75, Diabetes, Stroke alcohol concomitantly) score is recommended for the prediction of bleeding risk 7) . In Japanese guidelines 8) , the use of dabigatran or apixaban is recommended for patients with AF with CHADS 2 scores ≥1. Asian and European guidelines describe that the use of DOACs should be considered for patients with AF with CHA 2 DS 2 -VASc scores ≥1 for males or ≥2 for females 7, 9) . American guidelines recommend the use of DOACs for patients with AF with CHA 2 DS 2 -VASc scores ≥2 for males or ≥3 for females 10) . HAS-BLED scores ≥3 suggest a high risk of bleeding, but do not preclude the use of DOACs 7) . Such patients should undergo regular review and follow-up of the modifiable bleeding risk factors 7) .
Practical Guide to Choosing Dabigatran 150 mg Twice Daily or Apixaban 5 mg Twice Daily for Patients with AF
Based on previous reports [3] [4] [5] [6] , we recommend the use of dabigatran 150 mg twice daily for patients with AF who have a high risk of embolism (e.g., ischemic stroke on warfarin, apixaban, rivaroxaban, or edoxaban 3, 5) ; presence of left atrial appendage thrombus 4) ; or CHADS 2 scores ≥5 6) ) and a low risk of bleeding (age <75 years, no previous gastrointestinal bleeding, HAS-BLED scores ≤2, and creatinine clearance >50 mL/min) ( Table 1) . However, the prevalence of such patients with AF is considered low because patients with AF with a high risk of embolism usually have a high risk of bleeding 11) . In most other patients with AF, the use of apixaban 5 mg twice daily should be considered (Table 1) . Unlike apixaban, dabigatran has no indications for venous thromboembolism and cannot be crushed and delivered via feeding tubes 3) . However, dabigatran has the only approved antidote, idatucizumab. Direct head-to-head comparison of DOACs in the future may clarify the best anticoagulation therapy for patients with AF.
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